Program Access

Program Description

In this video panel activity, experts review the interplay between chronic kidney disease (CKD) and cardiovascular disease in patients with type 2 diabetes (T2DM), highlighting the importance of screening for CKD. They then discuss the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of kidney and cardiovascular health for patients with T2DM.

Upon completion of this activity, participants should be better able to:

• Recognize the relationship between kidney disease, T2DM, cardiovascular risks, and the importance of screening
• Discuss the clinical evidence, with the focus on renal outcomes, with SGLT2 inhibitors in patients with T2DM
• Evaluate the role of SGLT2 inhibitors in improving renal and cardiovascular health in patients with T2DM treated in primary care

Target Audience

This activity has been designed to meet the educational needs of Canadian primary care physicians involved in the management of patients with T2DM.

Credit

This 1.0-credit-per-hour Self-Learning activity has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 0.5 Mainpro+ certified credits.

This Mainpro+ activity is jointly provided by the Canadian Collaborative Research Network (CCRN) and PeerVoice.